(RTTNews) - Wednesday. Eli Lilly and Company (LLY) reported detailed results from the Phase 3 ACHIEVE-4 trial showing that Foundayo (orforglipron) demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in adults with type 2 diabetes and obesity or ov
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.